Page 37 - 2019_03-Haematologica-web

HBV reactivation
weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepati- tis B virus infection. J Hepatol. 2018;68(4): 672-681.
77. Buti M, Gane R, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):196-206.
78. Chan HL, Fung S, Seto WK, et al. Tenofovir alafenamide versus tenofovir disoproxil
fumarate for the treatment for HBeAg-posi- tive chronic hepatitis B virus infection: a ran- domised, double-blind, phase 3, non-inferi- ority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185-195.
79. Myers RP, Swain MG, Urbanski SJ, et al. Reactivation of hepatitis B e antigen-nega- tive chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal. Can J Gastroenterol. 2001;15 (9):599-603.
80. Takahata M, Hashino S, Onozawa M, et al. Hepatitis B virus (HBV) reverse seroconver-
sion (RS) can be prevented even in non- responders to hepatitis B vaccine after allo- geneic stem cell transplantation: long-term analysis of intervention in RS with vaccine for patients with previous HBV infection. Transpl Infect Dis. 2014; 16(5):797-801.
81. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipient with pre- vious HBV infection. Biol Blood Marrow Transplant. 2008;14(11):1226-1230.
haematologica | 2019; 104(3)
443